<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02968329</url>
  </required_header>
  <id_info>
    <org_study_id>JJBV544</org_study_id>
    <nct_id>NCT02968329</nct_id>
  </id_info>
  <brief_title>Left Atrial Function in Recurrent Stroke of Unknown Cause</brief_title>
  <official_title>Left Atrial Function as Predictor of Recurrent Stroke or Paroxysmal Atrial Fibrillation in Patients With Cryptogenic Stroke</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hasselt University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Jessa Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hasselt University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Stroke is an important cause of disability and the third leading cause of death.&#xD;
&#xD;
      Approximately 30 to 40 % of all strokes are estimated to be cryptogenic (i.e. no cause can be&#xD;
      found). There have been few previous studies regarding risk stratification for stroke&#xD;
      recurrence in patients with cryptogenic stroke.&#xD;
&#xD;
      Recent studies have suggested that left atrial (LA) function is an important determinant of&#xD;
      stroke risk. However, most studies focus on volume indices and LA dimensions, we also want to&#xD;
      investigate other echocardiographic parameters. The aim of this study is to assess the&#xD;
      predictive value of left atrial function for the risk of stroke recurrence and/or atrial&#xD;
      fibrillation by transthoracic echocardiography in cryptogenic stroke patients with no proven&#xD;
      atrial fibrillation (AF) and no indication for anticoagulants.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study design and population The investigators used a retrospective mono-centric case-control&#xD;
      design and analyzed all patients admitted for cerebrovascular accident (CVA) or transient&#xD;
      ischemic attack (TIA) between 2011 and 2014. The investigators searched for patients who had&#xD;
      a recurrent CVA/TIA and/or who were diagnosed with newly documented AF during the study&#xD;
      duration. Clinical, demographic and laboratory parameters were assessed. Echocardiographic&#xD;
      parameters, measured on first admission, were analyzed using EchoPAC version 112.&#xD;
&#xD;
      Statistical analysis Univariate analysis was performed for all covariates using the Cox&#xD;
      proportional hazards model. Likelihood ratio tests were used to determine significance for&#xD;
      all parameters.&#xD;
&#xD;
      If covariates were significant at the 25% significance level, they were used in the&#xD;
      multivariate model.&#xD;
&#xD;
      Multivariate analysis was performed using the Cox proportional hazards model with backward&#xD;
      elimination model selection. The Wald Chi-Square test was used to determine significance at&#xD;
      5% significance level. The program used for analysis is SAS version 9.4.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 2016</start_date>
  <completion_date type="Actual">April 2017</completion_date>
  <primary_completion_date type="Actual">April 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Recurrent ischemic CVA or TIA</measure>
    <time_frame>up to four years</time_frame>
    <description>Recurrent ischemic CVA or TIA from first ischemic CVA or TIA after 31-12-2010 until date of first documented recurrence, assessed up to four years</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>'New' diagnosis of AF</measure>
    <time_frame>Up to four years</time_frame>
    <description>'New' diagnosis of AF from first ischemic CVA or TIA after 31-12-2010 until date of documented 'new' AF, assessed up to four years</description>
  </secondary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Actual">500</enrollment>
  <condition>Stroke</condition>
  <arm_group>
    <arm_group_label>CVA cases</arm_group_label>
    <description>patients who experienced an ischemic CVA or TIA during the study duration and experienced a recurrence.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CVA controls</arm_group_label>
    <description>patients who experienced an ischemic CVA or TIA during the study duration, but who didn't experience a recurrence.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AF cases</arm_group_label>
    <description>patients who experienced an ischemic CVA or TIA during the study duration and who got diagnosed with 'new' AF</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AF controls</arm_group_label>
    <description>patients who experienced an ischemic CVA or TIA during the study duration but who didn't get diagnosed with 'new' AF during the study duration</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with Cryptogenic Stroke&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  CVA&#xD;
&#xD;
          -  TIA&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  proven AF or atrial flutter&#xD;
&#xD;
          -  prior ablation for AF&#xD;
&#xD;
          -  valvular disease&#xD;
&#xD;
          -  artificial heart valves&#xD;
&#xD;
          -  endocarditis&#xD;
&#xD;
          -  presence of an atrial septum defect or moderate to large patent foramen ovale&#xD;
&#xD;
          -  LV akinesia&#xD;
&#xD;
          -  moderate to severe carotid stenosis&#xD;
&#xD;
          -  prior surgery for carotid artery stenosis&#xD;
&#xD;
          -  total occlusion of the internal carotid artery&#xD;
&#xD;
          -  carotid artery dissection&#xD;
&#xD;
          -  vertebral artery dissection&#xD;
&#xD;
          -  massive aortic atheromatosis&#xD;
&#xD;
          -  temporal arteritis&#xD;
&#xD;
          -  basilar artery aneurysm&#xD;
&#xD;
          -  ascending aortic aneurysm&#xD;
&#xD;
          -  subclavian steal&#xD;
&#xD;
          -  prior CVA/TIA&#xD;
&#xD;
          -  intracerebral hemorrhage&#xD;
&#xD;
          -  lacunar infarction&#xD;
&#xD;
          -  clotting disorder&#xD;
&#xD;
          -  on anticoagulants&#xD;
&#xD;
          -  CVA/TIA as a procedural complication&#xD;
&#xD;
          -  hyperthyroidism&#xD;
&#xD;
          -  patients who died in hospital after first admission for CVA/TIA&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paul Dendale, prof. dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Jessa Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Bram Verdonck, student</last_name>
    <role>Study Chair</role>
    <affiliation>Hasselt University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jens Jeurissen, student</last_name>
    <role>Study Chair</role>
    <affiliation>Hasselt University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Jessa Ziekenhuis</name>
      <address>
        <city>Hasselt</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <study_first_submitted>November 13, 2016</study_first_submitted>
  <study_first_submitted_qc>November 16, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 18, 2016</study_first_posted>
  <last_update_submitted>August 9, 2017</last_update_submitted>
  <last_update_submitted_qc>August 9, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 10, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hasselt University</investigator_affiliation>
    <investigator_full_name>prof. dr. Paul Dendale</investigator_full_name>
    <investigator_title>prof. dr.</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

